A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/19/2009	US20090286863 Sulfamatobenzothiophene derivatives
11/19/2009	US20090286862 Therapeutic agent for psychoneurotic disease
11/19/2009	US20090286840 Polo-like kinase inhibitors such as 5-(5-Amino-2H-pyrazol-3-yl)-3-[1-(2-chloro-phenyl)-ethoxy]-thiophene-2-carboxylic acid amide, useful for treating or preventing autoimmune, inflammatory, proliferative or hyperproliferative disease, a neurodegenerative disease, or an immunologically-mediated disease
11/19/2009	US20090286833 Substituted Cyclohexylmethyl Compounds
11/19/2009	US20090286831 VR1 Receptor Ligands and u-Opioid Receptor Ligands for the Treatment of Pain
11/19/2009	US20090286829 Quinolynylmethylimidizoles as therapeutic agents
11/19/2009	US20090286820 (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use
11/19/2009	US20090286811 Fused pyrimidineone compounds as trpv3 modulators
11/19/2009	US20090286809 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
11/19/2009	US20090286805 Solubiliazation preparation
11/19/2009	US20090286801 Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
11/19/2009	US20090286796 Compounds exhibiting type X sPLA2 inhibiting effect
11/19/2009	US20090286794 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
11/19/2009	US20090286793 Pde4b inhibitors and uses therefor
11/19/2009	US20090286780 2-oxochromene derivatives
11/19/2009	US20090286775 Bicyclic Derivatives as P38 Kinase Inhibitors
11/19/2009	US20090286772 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
11/19/2009	US20090286771 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders
11/19/2009	US20090286746 Small Survival-Promoting/Immunomodulatory Peptide for Treatment of Brain Damage, Neurodegenerative Disorders, and Inflammatory Disorders
11/19/2009	US20090286741 Methods for improving the structure and function of arterioles
11/19/2009	US20090286736 using polypeptide comprising a membrane translocation domain and a NF- kappa B Essential Modulator (NEMO) binding sequence; comprising a NEMO binding domain (NBD)
11/19/2009	US20090286732 Compounds for delivery of therapeutic and imaging moieties to nerve cells
11/19/2009	US20090286715 Pharmaceutical Composition
11/19/2009	US20090285969 Pasteurisation process for microbial cells and microbial oil
11/19/2009	US20090285919 Rice Bran Extracts for Inflammation and Methods of Use Thereof
11/19/2009	US20090285910 Composition Comprising the Extract of Dioscorea Opposita Thunb Showing Neuronal Cell-Protecting Activity for Preventing and Treating Brain Disease
11/19/2009	US20090285909 Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
11/19/2009	US20090285888 Derivatives of dihydroxyphenylalanine
11/19/2009	US20090285822 Prevention and treatment of amyloidogenic disease
11/19/2009	US20090285816 Albumin Fusion Proteins
11/19/2009	US20090285809 Prevention and treatment of amyloidogenic diseases
11/19/2009	US20090285804 Anti-ADDLs antibodies and uses thereof
11/19/2009	US20090285803 ANTI-PirB ANTIBODIES
11/19/2009	US20090285790 Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders
11/19/2009	DE112007003136T5 Ein Extrakt An extract
11/19/2009	CA2740029A1 Pharmaceutical composition for treatment of fibromyalgia
11/19/2009	CA2725416A1 Compounds for improving learning and memory
11/19/2009	CA2724483A1 Treatment for epilepsy
11/19/2009	CA2724442A1 A drilling rig and a method for moving a drilling rig
11/19/2009	CA2724435A1 Selective subtype alpha 2 adrenergic agents and methods for use thereof
11/19/2009	CA2724413A1 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
11/19/2009	CA2724332A1 Method of treatment
11/19/2009	CA2724219A1 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
11/19/2009	CA2724055A1 Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2 -dihydroquinoline derivatives having substituted oxy group
11/19/2009	CA2724048A1 Oral preparation
11/19/2009	CA2723987A1 Use of angiogenin or angiogenin agonists for treating diseases and disorders
11/19/2009	CA2723649A1 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
11/19/2009	CA2723623A1 Therapeutic agent for pain
11/19/2009	CA2723430A1 Anti-pirb antibodies
11/18/2009	EP2119738A1 Polyethylene glycol derivative
11/18/2009	EP2119718A1 Macrocyclic compound
11/18/2009	EP2119716A1 Aza-bridged-ring compound
11/18/2009	EP2119704A1 Acylguanidine derivative
11/18/2009	EP2119702A1 Amide derivative
11/18/2009	EP2119476A2 Amide derivatives as positive allosteric modulators and methods of use thereof
11/18/2009	EP2119444A1 Therapeutic agent for pain disease
11/18/2009	EP2119440A1 Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease
11/18/2009	EP2119437A1 Device for the transdermal administration of bisoprolol
11/18/2009	EP2118103A2 Azaindole derivatives as cftr modulators
11/18/2009	EP2118101A1 Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
11/18/2009	EP2118068A1 Indazoles used to treat estrogen receptor beta mediated disorders
11/18/2009	EP2118067A1 Nicotinic acetylcholine receptor modulators
11/18/2009	EP2117562A1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
11/18/2009	EP2117560A1 A composition for selective serotonin reuptake inhibition and process thereof
11/18/2009	EP2117550A1 Use of ranolazine for the treatment of non-coronary microvascular diseases
11/18/2009	EP2117547A1 1,2,3,4-tetrahydroisoquinoline derivatives having effects of preventing and treating degenerative and inflammatory diseases
11/18/2009	EP2117540A1 New use of glutaminyl cyclase inhibitors
11/18/2009	EP2117536A2 Cosmetic and pharmaceutical applications of n-acylated amino acids and structurally related compounds
11/18/2009	EP2117535A1 Novel pharmaceutical compositions
11/18/2009	EP2117527A1 Methods for the treatment of senile dementia of the alzheimer's type
11/18/2009	EP1963278B1 Substituted imidazoline derivatives
11/18/2009	EP1910340B1 Indazolecarboxamide derivatives as 5ht4 receptor agonists
11/18/2009	EP1888538B1 (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor
11/18/2009	EP1768958B1 New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
11/18/2009	EP1765779B1 New substituted piperidines as modulators of dopamine neurotransmission
11/18/2009	EP1615893B1 2-azabicyclo¬3.3.1 nonane derivatives as opioid receptor antagonists
11/18/2009	EP1529049B1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
11/18/2009	EP1490064B1 Substituted pyridinones as modulators of p38 map kinase
11/18/2009	EP1442026B9 Triazole derivatives as cyclooxygenase (cox) inhibitors
11/18/2009	EP1421071B1 Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
11/18/2009	EP1397357B9 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
11/18/2009	EP1306372B1 Heterocycle derivatives and drugs
11/18/2009	EP1280781B1 5-ht 7 receptor antagonists
11/18/2009	EP0957901B1 Pharmaceutical preparations of glutathione and methods of administration thereof
11/18/2009	EP0760811B1 Imidazole derivatives as histamine receptor h3 modulators
11/18/2009	CN101583615A Spiropiperidine glycinamide derivatives
11/18/2009	CN101583609A Indoles
11/18/2009	CN101583601A Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
11/18/2009	CN101583596A N-substituted-azacyclylamines as histamine-3 antagonists
11/18/2009	CN101580525A Method for extracting salidroside, polysaccharose and tannin-type substances from rhodiola root crude drugs
11/18/2009	CN101580482A Method for preparing rivastigmine hydrogen tartrate and application thereof
11/18/2009	CN101579511A Drug combination used for treating schizophrenia
11/18/2009	CN101579450A Traditional Chinese medicine for treating headache
11/18/2009	CN101579387A Medicinal composition for treating anorexia nervosa and preparation method thereof
11/18/2009	CN101579386A Medicinal composition for treating anorexia nervosa
11/18/2009	CN101579379A Medicinal composition for treating senile dementia and preparation method thereof
11/18/2009	CN101579378A Medicinal dripping pill for treating senile dementia
11/18/2009	CN101579377A Medicinal composition for treating senile dementia
11/18/2009	CN101579356A Deproteinated calf blood ingredient brain targeting nanosphere and preparation method thereof
11/18/2009	CN101579355A Nutrition composition used for maintaining functions of mitochondria and application thereof

1 ... 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 ... 1833